Join Us

Biosimilars Policy Forum

Learn more about the forum held in Washington D.C., on February 27, 2012. Read More

FDA Draft Biosimilar Guidance

Read More

Meet
Dr. Dolinar

Alliance Chairman, Dr. Richard Dolinar Read More

Putting Patients First

How to ensure safe biologics. Read More

The Issue

Learn more about safe biologics and how it
affects you. Read More

Get The Facts

Explore our Information Center. Read More

The Issue

Biologics are advanced prescription drugs to treat cancer, rheumatoid arthritis and other debilitating diseases. In November 2010, the Food and Drug Administration began consultation with patient groups, physicians and industry on how to approve the first copies of these drugs, known as follow-on biologics or biosimilars. As the FDA moves forward in implementing this pathway, the Alliance for Safe Biologic Medicines will work to ensure patient safety remains the priority. LEARN MORE

Get Involved

Sign up for updates

Latest News
Dr. Dolinar Pens Article for BIO Newsletter
May 17th, 2012 Read More
ASBM Highlighted in Inside Health Policy Article
May 16th, 2012 Read More
ASBM’s Dr. Dolinar quoted in PharmaTimes
May 16th, 2012 Read More
Member Partners

The Alliance for Safe Biologic Medicines is an organization composed of diverse healthcare groups—from patients to physicians, innovative medical biotechnology companies, and others who are working together to ensure patient safety is at the forefront of the biosimilars policy discussion. Read More

Press Releases
Alliance for Safe Biologic Medicines Chairman Urges FDA to Ensure that Patient Safety is the Cornerstone of Biosimilar Pathway
May 16th, 2012 Read More
Alliance for Safe Biologic Medicines Welcomes FDA Biosimilars Draft Guidance, Urges Cautious Approach to Ensure Patient Safety
April 16th, 2012 Read More